Clinical Development - Over 100 patients have been treated with AlloNK across autoimmune and oncology indications[1] - AlloNK received FDA Fast Track Designation for refractory rheumatoid arthritis (RA), marking it as the first therapy in the deep B-cell depletion category to achieve this[3] - Initial clinical response data for more than 15 refractory RA patients is expected in the first half of 2026[2] - The company plans to engage with the FDA in the first half of 2026 to discuss pivotal trial design for AlloNK in refractory RA[3] - Artiva's pipeline includes CAR-NK candidates targeting both solid and hematologic cancers[6] Financial Performance - Cash, cash equivalents, and investments totaled $123.0 million as of September 30, 2025, providing a cash runway into Q2 2027[9] - Research and development expenses increased to $17.6 million for Q3 2025, up from $13.5 million in Q3 2024[9] - General and administrative expenses rose to $5.3 million for Q3 2025, compared to $4.8 million in Q3 2024[9] - Net loss for Q3 2025 was $21.5 million, compared to a net loss of $17.5 million in Q3 2024[9] - Total operating expenses for Q3 2025 were $22.9 million, up from $18.3 million in Q3 2024[13]
Artiva Biotherapeutics, Inc.(ARTV) - 2025 Q3 - Quarterly Results